Receptos

Receptos was a San Diego-based biopharmaceutical company specializing in immunology and metabolic disease drug discovery and development. Its lead compound, ozanimod (RPC1063), was a selective S1P receptor modulator in clinical trials for multiple sclerosis and ulcerative colitis. Founded in 2009 and based in San Diego, California, Receptos went public and built a pipeline around GPCR-targeted small-molecule therapies. The company was acquired by Celgene Corporation in July 2015 for approximately $7.2–7.3 billion, one of the largest biotech acquisitions of that year. Receptos subsequently became a wholly-owned subsidiary of Celgene, and later of Bristol Myers Squibb following Celgene's acquisition. Ozanimod was eventually approved by the FDA as Zeposia.